283 related articles for article (PubMed ID: 23099329)
1. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.
Schmidt CS; White CJ; Ibrahim AS; Filler SG; Fu Y; Yeaman MR; Edwards JE; Hennessey JP
Vaccine; 2012 Dec; 30(52):7594-600. PubMed ID: 23099329
[TBL] [Abstract][Full Text] [Related]
2. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
Ibrahim AS; Luo G; Gebremariam T; Lee H; Schmidt CS; Hennessey JP; French SW; Yeaman MR; Filler SG; Edwards JE
Vaccine; 2013 Nov; 31(47):5549-56. PubMed ID: 24063977
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
Landrum ML; Lalani T; Niknian M; Maguire JD; Hospenthal DR; Fattom A; Taylor K; Fraser J; Wilkins K; Ellis MW; Kessler PD; Fahim RE; Tribble DR
Hum Vaccin Immunother; 2017 Apr; 13(4):791-801. PubMed ID: 28010246
[TBL] [Abstract][Full Text] [Related]
4. Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.
Segal E
Methods Mol Biol; 2017; 1625():343-353. PubMed ID: 28585001
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.
Harro C; Betts R; Orenstein W; Kwak EJ; Greenberg HE; Onorato MT; Hartzel J; Lipka J; DiNubile MJ; Kartsonis N
Clin Vaccine Immunol; 2010 Dec; 17(12):1868-74. PubMed ID: 20943877
[TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.
Chen WH; Pasetti MF; Adhikari RP; Baughman H; Douglas R; El-Khorazaty J; Greenberg N; Holtsberg FW; Liao GC; Reymann MK; Wang X; Warfield KL; Aman MJ
Clin Vaccine Immunol; 2016 Dec; 23(12):918-925. PubMed ID: 27707765
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
8. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.
Lin L; Ibrahim AS; Xu X; Farber JM; Avanesian V; Baquir B; Fu Y; French SW; Edwards JE; Spellberg B
PLoS Pathog; 2009 Dec; 5(12):e1000703. PubMed ID: 20041174
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
Creech CB; Frenck RW; Sheldon EA; Seiden DJ; Kankam MK; Zito ET; Girgenti D; Severs JM; Immermann FW; McNeil LK; Cooper D; Jansen KU; Gruber W; Eiden J; Anderson AS; Baber J
Vaccine; 2017 Jan; 35(2):385-394. PubMed ID: 27866765
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
Frenck RW; Creech CB; Sheldon EA; Seiden DJ; Kankam MK; Baber J; Zito E; Hubler R; Eiden J; Severs JM; Sebastian S; Nanra J; Jansen KU; Gruber WC; Anderson AS; Girgenti D
Vaccine; 2017 Jan; 35(2):375-384. PubMed ID: 27916408
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.
Harro CD; Betts RF; Hartzel JS; Onorato MT; Lipka J; Smugar SS; Kartsonis NA
Vaccine; 2012 Feb; 30(9):1729-36. PubMed ID: 22192849
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
Levy J; Licini L; Haelterman E; Moris P; Lestrate P; Damaso S; Van Belle P; Boutriau D
Hum Vaccin Immunother; 2015; 11(3):620-31. PubMed ID: 25715157
[TBL] [Abstract][Full Text] [Related]
14. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.
Spellberg B; Ibrahim AS; Yeaman MR; Lin L; Fu Y; Avanesian V; Bayer AS; Filler SG; Lipke P; Otoo H; Edwards JE
Infect Immun; 2008 Oct; 76(10):4574-80. PubMed ID: 18644876
[TBL] [Abstract][Full Text] [Related]
15. One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.
Mancini F; Monaci E; Lofano G; Torre A; Bacconi M; Tavarini S; Sammicheli C; Arcidiacono L; Galletti B; Laera D; Pallaoro M; Tuscano G; Fontana MR; Bensi G; Grandi G; Rossi-Paccani S; Nuti S; Rappuoli R; De Gregorio E; Bagnoli F; Soldaini E; Bertholet S
PLoS One; 2016; 11(1):e0147767. PubMed ID: 26812180
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a novel chimeric B cell epitope-based vaccine against mastitis induced by either Streptococcus agalactiae or Staphylococcus aureus in mice.
Xu H; Hu C; Gong R; Chen Y; Ren N; Xiao G; Xie Q; Zhang M; Liu Q; Guo A; Chen H
Clin Vaccine Immunol; 2011 Jun; 18(6):893-900. PubMed ID: 21508165
[TBL] [Abstract][Full Text] [Related]
17. Protective efficacy of Hla-MntC-SACOL0723 fusion protein adjuvanted in alum and MPL against Staphylococcus aureus sepsis infection in mice.
Ghaedi T; Davoodian P; Hassaniazad M; Eftekhar E; Faezi S; Abparvar AA; Einakian MA; Ahmadi K
J Immunol Methods; 2021 Jul; 494():113055. PubMed ID: 33857474
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
19. Development and evaluation of vaccine against Staphylococcus aureus recovered from naturally occurring mastitis in she-camels.
Aqib AI; Anjum AA; Ijaz M; Hussain R; Ahmed R; Farooqi SH; Aslam HB; Hussain K; Mehmood K; Zhang H
Microb Pathog; 2018 Apr; 117():341-347. PubMed ID: 29510207
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with Secreted Aspartyl Proteinase 2 Protein from
Shukla M; Rohatgi S
Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32661125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
